The Beauty Health Company (NASDAQ: SKIN) is a global beauty and health company, which primarily relies on its flagship brand, HydraFacial, a skin product developed using a patented Vortex-Fusion Delivery System to clean, exfoliate, extract, and hydrate skin. HydraFacial is available in more than 90 counties.
Shares of the skin care company are soaring 31% through early trading on Wednesday, February 23, 2022. Over the past three months, The Beauty Health Company has seen average daily volume of around 2.16 million shares. However, volume of 3.73 million shares or dollar volume of around $63.6 million, has already exchanged hands through early trading Wednesday.
The global skin care company is seeing shares rally after the company reported record fourth quarter and fiscal year 2021 financial results. For the fiscal year 2021, The Beauty Health Company reported net sales growth of 118.3% to $260.1 million. Adjusted EBITDA came in at $32.7 million, an increase of 12.6% compared to 2020.
During the fourth quarter, the company reported net sales of $77.9 million, which represents year-over-year growth of 105.6%. Gross margins improved to 72.9% compared to 67.8% last year. The Beauty Health Company did report a net loss of $17.3 million, compared to a loss of $7.5 million during the fourth quarter of 2022.
Management issued strong fiscal 2022 guidance, which predicts another year of record growth ahead. Fiscal 2022 net sales are estimated to come in somewhere between $320 million and $330 million. Adjusted EBITDA estimates reach $50 million for the current fiscal year.
“We are extremely pleased with our accomplishments this quarter and for the full year 2021, exceeding our guidance. Importantly, we navigated through macro challenges and COVID, delivering strong results by executing against our key strategic initiatives. Our performance is proof of the compelling opportunity we have to capture the convergence of medical aesthetics and skincare,” said Brent Saunders, Beauty Health’s Executive Chairman.
Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/
